Related Experiment Video
Updated: Jun 18, 2026
09:20
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
Early vasoactive drugs improve heart failure outcomes
William Frank Peacock1, Charles Emerman, Maria R Costanzo
1Department of Emergency Medicine, The Cleveland Clinic, Cleveland, OH 44195, USA. peacocw@ccf.org
Congestive Heart Failure (Greenwich, Conn.)
|November 21, 2009
Summary
Early administration of vasoactive therapy in acute decompensated heart failure (ADHF) is linked to better patient outcomes. Delayed treatment increases the risk of in-hospital mortality for ADHF patients.
Area of Science:
- Cardiology
- Clinical Medicine
- Pharmacology
Background:
- Vasoactive therapy is a cornerstone in managing acute decompensated heart failure (ADHF).
- The timing of initiating vasoactive agents may significantly impact patient prognosis.
Purpose of the Study:
- To investigate the association between the time to vasoactive therapy and clinical outcomes in ADHF patients.
- To determine if early initiation of vasoactive agents improves inpatient mortality rates.
Main Methods:
- Analysis of data from the Acute Decompensated Heart Failure (ADHERE) Registry.
- Comparison of in-hospital mortality between patients receiving early (<6 hours) versus late vasoactive therapy.
- Statistical analysis to assess the relationship between treatment delay and mortality risk.
Main Results:
- Vasoactive agents were administered early in 63.8% of patients and late in 36.2%.
- Early vasoactive therapy (median 1.7 hours) was associated with significantly lower in-hospital mortality compared to late therapy (median 14.7 hours).
- Each 6-hour delay in treatment increased the adjusted odds of death by 6.8% (P<.0001).
Conclusions:
- Early initiation of vasoactive therapy in hospitalized ADHF patients is associated with improved clinical outcomes.
- Timely administration of vasoactive agents is crucial for reducing mortality in ADHF.
- Reducing delays in vasoactive treatment can enhance patient survival in ADHF.
Related Concept Videos
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.